|1.||Puri, Raj K: 36 articles (07/2015 - 02/2002)|
|2.||Pastan, Ira: 18 articles (06/2015 - 07/2002)|
|3.||Kreitman, Robert J: 17 articles (06/2015 - 04/2002)|
|4.||Kawakami, Koji: 12 articles (12/2008 - 02/2002)|
|5.||Puri, R K: 12 articles (01/2003 - 03/2000)|
|6.||Joshi, Bharat H: 11 articles (07/2015 - 06/2002)|
|7.||Schlievert, Patrick M: 10 articles (01/2015 - 10/2004)|
|8.||Husain, Syed R: 9 articles (01/2013 - 03/2003)|
|9.||Onda, Masanori: 8 articles (07/2012 - 07/2002)|
|10.||Leland, Pamela: 7 articles (12/2014 - 06/2002)|
11/01/2002 - "choshinensis-derived mCTA/LTB is an effective and safe mucosal adjuvant for the induction of protective immunity against potent bacterial exotoxin and influenza virus infection."
06/01/1983 - "Serial antibody titers to exotoxin A provided serologic confirmation of invasive disease, distinguished infection from colonization, and, in the case of decreasing titers, indicated successful therapy. "
01/01/1981 - "Passive or active immunization against this toxin gives significant protection against experimental infections with exotoxin-producing strains. "
01/01/2015 - "Group A streptococcus (GAS) is an important human pathogen that produces several extracellular exotoxins to facilitate invasion and infection. "
09/01/2013 - "Exotoxins have been implicated in the pathogenesis of this infection; however, the cellular mechanisms responsible remain largely undefined. "
02/28/2015 - "We show that both anthrax pores and the translocation domain of Pseudomonas exotoxin A (ETA) efficiently deliver DARPins into the cytosol. "
01/01/2015 - "Bacillus anthracis is a Gram-positive bacterium that causes anthrax, mainly in herbivores through exotoxins and capsule produced on plasmids, pXO1 and pXO2. "
09/05/2013 - "Bacillus anthracis, the causative agent of anthrax disease, is lethal owing to the actions of two exotoxins: anthrax lethal toxin (LT) and oedema toxin (ET). "
01/01/2012 - "Bacillus anthracis, the causative agent of anthrax, secretes a tri-partite exotoxin that exerts pleiotropic effects on the host. "
01/01/2012 - "Cellular and physiological effects of anthrax exotoxin and its relevance to disease."
11/01/2015 - "In this study, a three-dimensional (3D) tissue model composed of human lung epithelial cells and fibroblasts was used to delineate the role of specific staphylococcal exotoxins in tissue pathology associated with severe pneumonia. "
05/31/2003 - "aureus exotoxin that is associated with fulminant necrotising pneumonia. "
03/01/2002 - "aeruginosa lipopolysaccharide (LPS), phosholipase C (PLC), and exotoxin A (ETA) were evaluated for their ability to induce pulmonary inflammation in mice following intranasal inoculation. "
09/01/2001 - "Impairment of host defence by exotoxin A in Pseudomonas aeruginosa pneumonia in mice."
08/01/2011 - "The type III secretion system, a needle-complex, allows exotoxin injections into eukaryotic cells and is involved in the pathogenesis of acute pneumonia. "
|4.||Hairy Cell Leukemia
08/01/2013 - "Phase I trials of moxetumomab pasudotox, an ADC which combines anti-CD22 with PE38, a fragment of Pseudomonas exotoxin A, have been completed in hairy cell leukemia with a ORR of 86 %. "
01/01/2006 - "Another, containing an anti-CD22 Fv and truncated Pseudomonas exotoxin, has induced complete remissions in a high proportion of cases of hairy-cell leukemia. "
10/01/2009 - "Immunoconjugate Therapy with BL22 (anti-CD22 [corrected] antibody linked to truncated to Pseudomonas exotoxin) represents the newest milestone in the development of effective treatment for hairy cell leukemia."
05/01/2010 - "In early clinical trials, immunotoxins constructed with domains II and III of Pseudomonas exotoxin (termed PE38), have produced a high rate of complete remissions in Hairy Cell Leukemia and objective responses in other malignancies. "
10/01/2006 - "Recombinant immunotoxin BL22 is an anti-CD22 Fv fragment fused to truncated Pseudomonas exotoxin; it induces complete remissions in a high percentage of patients with chemoresistant hairy cell leukemia. "
|5.||Melanoma (Melanoma, Malignant)
07/01/2009 - "We have studied the effects of a chemical conjugate of pseudomonas exotoxin A (PE) and the antibody 9.2.27, which recognizes the high molecular weight melanoma associated antigen (HMW-MAA) expressed in most malignant melanomas and melanoma cell lines. "
06/01/1995 - "An immunotoxin conjugate has been prepared by linking an internalizing antibody with melanoma selectivity, ME20, with a binding-defective form of Pseudomonas exotoxin A, LysPE40. "
04/01/2008 - "A recombinant immunotoxin was constructed by fusing a single chain fragment variable antibody fragment, specific for the melanoma-associated chondroitin sulfate proteoglycan (MCSP), to a truncated variant of Pseudomonas exotoxin A (ETA'), carrying a C-terminal KDEL-peptide for improved retrograde intracellular transport. "
04/01/1994 - "In vivo efficacy of intrathecal transferrin-Pseudomonas exotoxin A immunotoxin against LOX melanoma."
04/01/2010 - "We have earlier shown that the 9.2.27 Pseudomonas Exotoxin A (PE) immunotoxin (IT) efficiently kills melanoma cells through inhibition of protein synthesis followed by some morphologic and biochemical features of apoptosis, a different cell killing mechanism than the one caused by Dacarbazine (DTIC), a chemotherapeutic drug used to treat malignant melanoma. "
|5.||Interleukin-4 (Interleukin 4)
|8.||Immunoglobulin E (IgE)
|10.||anthrax toxin (anthrax lethal factor)
|1.||Drug Therapy (Chemotherapy)
|4.||Heterologous Transplantation (Xenotransplantation)